Research development of biological profile of male breast cancer

doi:10.3877/cma.j.issn.1674-0793.2019.01.012

Abstract

Abstract:

Male breast cancer (MBC) is a rare and special male malignant tumor whose morbidity is much lower than that of female breast cancer (FBC) due to the different physiological factors. There have been multiple well-meaning attempts to show that, after adjusting for stage and age, the prognosis of MBC is similar to that of FBC, but there are vast differences in the expression of hormone receptors, HER-2, Ki-67 and BCL2. With developments in molecular biology and the transcriptosomic landscape of breast malignancy, there will be an increase in our knowledge of the molecular differences between breast cancer in females and males. For MBC patients, these differences may be of great importance for the prognosis and systemic therapy. Summing up the relevant literatures in China and abroad in recent years, this paper provides an overview of the molecular biology research progress of MBC, in order to strengthen the understanding and attention of clinicians and patients for MBC.

Key words: Breast neoplasms, male, Neoplasm staging, Tumor markers, biological

Baozhong Yao, Liang Li, Jun Zhang, Ming Jiang. Research development of biological profile of male breast cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2019, 13(01): 54-57.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2019.01.012

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2019/V13/I01/54

References 33

[1]	Ryu SW, Ho K, O'Toole SA, et al. Case report of male breast cancer detected on magnetic resonance imaging[J]. J Med Imaging Radiat Oncol, 2017, 61(3): 369-371.
[2]	Feifei Zhou, Rong Huang, Jun Jiang, et al. A meta-analysis based on case-control studies shows the similar prognosis between male and female patients with breast cancer[J]. Chinese-German J Clin Oncol, 2011, 10(6): 311-316.
[3]	Chavez-Macgregor M, Clarke CA, Lichtensztajn D, et al. Male breast cancer according to tumor subtype and race: a population-based study[J]. Cancer, 2013, 119(9): 1611-1167.
[4]	Cutuli B, Le-Nir CC, Serin D, et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases[J]. Crit Rev Oncol Hematol, 2010, 73(3): 246-254.
[5]	Massarweh SA, Choi GL. Special considerations in the evaluation and management of breast cancer in men[J]. Curr Probl Cancer, 2016, 40(2-4): 163-171.
[6]	Shaaban AM, Ball GR, Brannan RA, et al. A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences[J]. Breast Cancer Res Treat, 2012, 133(3): 949-958.
[7]	Muir D, Kanthan R, Kanthan SC. Male versus female breast cancers. A population-based comparative immunohistochemical analysis[J]. Arch Pathol Lab Med, 2003, 127(1): 36-41.
[8]	Shandiz FH, Tavassoli A, Sharifi N, et al. Hormone receptor expression and clinicopathologic features in male and female breast cancer[J]. Asian Pac J Cancer Prev, 2015, 16(2): 471-474.
[9]	Humphries MP, Rajan SS, Honarpisheh H, et al. Characterisation of male breast cancer: a descriptive biomarker study from a large patient series[J]. Sci Rep, 2017, 7: 45293.
[10]	Kidwai N, Gong Y, Sun X, et al. Expression of androgen receptor and prostate-specific antigen in male breast carcinoma[J]. Breast Cancer Res, 2004, 6(1): R18-23.
[11]	Kwiatkowska E, Teresiak M, Filas V, et al. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients[J]. Clin Cancer Res, 2003, 9(12): 4452-4459.
[12]	Cardoso F, Bartlett JMS, Slaets L, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program[J]. Ann Oncol, 2018, 29(2): 405-417.
[13]	Ni M, Chen Y, Lim E, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer[J]. Cancer Cell, 2011, 20(1): 119-131.
[14]	O'Shaughnessy J, Campone M, Brain E, et al. Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer[J]. Ann Oncol, 2016, 27(1): 106-113.
[15]	Bloom KJ, Govil H, Gattuso P, et al. Status of HER-2 in male and female breast carcinoma[J]. Am J Surg, 2001, 182(4): 389-392.
[16]	Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci U. S. A, 2001, 98(19): 10869-10874.
[17]	Kornegoor R, Verschuur-Maes AHJ, Buerger H, et al. Immunophenotyping of male breast cancer[J]. Histopathology, 2012, 61(6): 1145-1155.
[18]	Nilsson C, Johansson I, Ahlin C, et al. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact[J]. Acta Oncol, 2013, 52(1): 102-109.
[19]	Abreu MH, Afonso N, Abreu PH, et al. Male breast cancer:looking for better prognostic subgroups[J]. Breast, 2016, 26: 18-24.
[20]	Schildhaus HU, Schroeder L, Merkelbach-Bruse S, et al. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes[J]. Breast, 2013, 22(6): 1066-1071.
[21]	Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer[J]. Breast Cancer Res, 2002, 4(1): R2.
[22]	Thompson D, Easton D, Breast Cancer Linkage Consortium.Variation in cancer risks, by mutation position, in BRCA2 mutation carriers[J]. Am J Hum Genet, 2001, 68(2): 410-419.
[23]	Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci[J]. Nature, 2007, 447(7148): 1087-1093.
[24]	Orr N, Cooke R, Jones M, et al. Genetic variants at chromosomes 2q35, 5p12, 6q25.1,10q26.13, and 16q12.1 influence the risk of breast cancer in men[J]. PLoS Genet, 2011, 7(9): e1002290..
[25]	Johansson I, Nilsson C, Berglund P, et al. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer[J]. Breast Cancer Res Treat, 2011, 129(3): 747-760.
[26]	Piscuoglio S, Ng CK, Murray MP, et al. The genomic landscape of male breast cancer[J]. Clin Cancer Res, 2016, 22(16): 4045-4056.
[27]	Lehmann U, Streichert T, Otto B, et al. Identification of differentially expressed microRNAs in male breast cancer[J]. BMC Cancer, 2010, 10: 109.
[28]	Fassan M, Baffa R, Palazzo JP, et al. MicroRNA expression profiling of male breast cancer[J]. Breast Cancer Res, 2009, 11(4): R58.
[29]	Pinto R, Pilato B, Ottini L, et al. Different methylation and microRNA expression pattern in male and female familial breast cancer[J]. J Cell Physiol, 2013, 228(6): 1264-1269.
[30]	Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J]. N Engl J Med, 2004, 351(27): 2817-2826.
[31]	Kiluk JV, Lee MC, Park CK, et al. Male breast cancer: management and follow-up recommendations[J]. Breast J, 2011, 17(5): 503-509.
[32]	Grenader T, Yerushalmi R, Tokar M, et al. The 21-gene recurrence score assay (Oncotype DX™) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort[J]. Oncology, 2014, 87(1): 1-6.
[33]	Humphries MP, Sundara Rajan S, Droop A, et al. A case-matched gender comparison transcriptomic screen identifies eIF4E and eIF5 as potential prognostic markers in male breast cancer[J]. Clin Cancer Res, 2017, 23(10): 2575-2583.

Please choose a citation manager

Content to export